Literature DB >> 22190397

Humoral and cellular immune responses to Yersinia pestis infection in long-term recovered plague patients.

Bei Li1, Chunhong Du, Lei Zhou, Yujing Bi, Xiaoyi Wang, Li Wen, Zhaobiao Guo, Zhizhong Song, Ruifu Yang.   

Abstract

Plague is one of the most dangerous diseases and is caused by Yersinia pestis. Effective vaccine development requires understanding of immune protective mechanisms against the bacterium in humans. In this study, the humoral and memory cellular immune responses in plague patients (n = 65) recovered from Y. pestis infection during the past 16 years were investigated using a protein microarray and an enzyme-linked immunosorbent spot assay (ELISpot). The seroprevalence to the F1 antigen in all recovered patients is 78.5%. In patients infected more than a decade ago, the antibody-positive rate still remains 69.5%. There is no difference in the antibody presence between gender, age, and infected years, but it seems to be associated with the F1 antibody titers during infection (r = 0.821; P < 0.05). Except F1 antibody, the antibodies against LcrV and YopD were detected in most of the patients, suggesting they could be the potential diagnostic markers for detecting the infection of F1-negative strains. Regarding cellular immunity, the cell number producing gamma interferon (IFN-γ), stimulated by F1 and LcrV, respectively, in vitro to the peripheral blood mononuclear cells of 7 plague patients and 4 negative controls, showed no significant difference, indicating F1 and LcrV are not dominant T cell antigens against plague for a longer time in humans. Our findings have direct implications for the future design and development of effective vaccines against Y. pestis infection and the development of new target-based diagnostics.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22190397      PMCID: PMC3272935          DOI: 10.1128/CVI.05559-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  35 in total

1.  Construction of defined F1 negative mutants of virulent Yersinia pestis.

Authors:  P L Worsham; M P Stein; S L Welkos
Journal:  Contrib Microbiol Immunol       Date:  1995

2.  Multidrug resistance in plague.

Authors:  D T Dennis; J M Hughes
Journal:  N Engl J Med       Date:  1997-09-04       Impact factor: 91.245

3.  Field evaluation of an immunoglobulin G anti-F1 enzyme-linked immunosorbent assay for serodiagnosis of human plague in Madagascar.

Authors:  B Rasoamanana; F Leroy; P Boisier; M Rasolomaharo; P Buchy; E Carniel; S Chanteau
Journal:  Clin Diagn Lab Immunol       Date:  1997-09

4.  An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model.

Authors:  E D Williamson; P M Vesey; K J Gillhespy; S M Eley; M Green; R W Titball
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

5.  Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis.

Authors:  G W Anderson; S E Leary; E D Williamson; R W Titball; S L Welkos; P L Worsham; A M Friedlander
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

6.  Immune response to Yersinia outer proteins and other Yersinia pestis antigens after experimental plague infection in mice.

Authors:  G E Benner; G P Andrews; W R Byrne; S D Strachan; A K Sample; D G Heath; A M Friedlander
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

7.  Antibody against V antigen prevents Yop-dependent growth of Yersinia pestis.

Authors:  Alexander V Philipovskiy; Clarissa Cowan; Christine R Wulff-Strobel; Sandra H Burnett; Edward J Kerschen; Donald A Cohen; Alan M Kaplan; Susan C Straley
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

8.  Protective efficacy of recombinant Yersinia outer proteins against bubonic plague caused by encapsulated and nonencapsulated Yersinia pestis.

Authors:  G P Andrews; S T Strachan; G E Benner; A K Sample; G W Anderson; J J Adamovicz; S L Welkos; J K Pullen; A M Friedlander
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

9.  Comparison of the immunological and protective responses elicited by microencapsulated formulations of the F1 antigen from Yersinia pestis.

Authors:  K M Reddin; T J Easterbrook; S M Eley; P Russell; V A Mobsby; D H Jones; G H Farrar; E D Williamson; A Robinson
Journal:  Vaccine       Date:  1998-05       Impact factor: 3.641

10.  Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine.

Authors:  D G Heath; G W Anderson; J M Mauro; S L Welkos; G P Andrews; J Adamovicz; A M Friedlander
Journal:  Vaccine       Date:  1998-07       Impact factor: 3.641

View more
  16 in total

1.  Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague.

Authors:  Danielle A Wagner; Sean M Kelly; Andrew C Petersen; Nathan Peroutka-Bigus; Ross J Darling; Bryan H Bellaire; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Acta Biomater       Date:  2019-10-11       Impact factor: 8.947

2.  Oral administration of a recombinant attenuated Yersinia pseudotuberculosis strain elicits protective immunity against plague.

Authors:  Wei Sun; Shilpa Sanapala; Hannah Rahav; Roy Curtiss
Journal:  Vaccine       Date:  2015-10-26       Impact factor: 3.641

3.  LcrV delivered via type III secretion system of live attenuated Yersinia pseudotuberculosis enhances immunogenicity against pneumonic plague.

Authors:  Wei Sun; Shilpa Sanapala; Jeremy C Henderson; Shandiin Sam; Joseph Olinzock; M Stephen Trent; Roy Curtiss
Journal:  Infect Immun       Date:  2014-08-11       Impact factor: 3.441

4.  A bivalent typhoid live vector vaccine expressing both chromosome- and plasmid-encoded Yersinia pestis antigens fully protects against murine lethal pulmonary plague infection.

Authors:  James E Galen; Jin Yuan Wang; Jose A Carrasco; Scott A Lloyd; Gabriela Mellado-Sanchez; Jovita Diaz-McNair; Olga Franco; Amanda D Buskirk; James P Nataro; Marcela F Pasetti
Journal:  Infect Immun       Date:  2014-10-20       Impact factor: 3.441

5.  A Combined YopB and LcrV Subunit Vaccine Elicits Protective Immunity against Yersinia Infection in Adult and Infant Mice.

Authors:  Shannon J Heine; Olga L Franco-Mahecha; Khandra T Sears; Cinthia B Drachenberg; Maarten L van Roosmalen; Kees Leenhouts; Wendy L Picking; Marcela F Pasetti
Journal:  J Immunol       Date:  2019-02-20       Impact factor: 5.422

Review 6.  Rational considerations about development of live attenuated Yersinia pestis vaccines.

Authors:  Wei Sun; Roy Curtiss
Journal:  Curr Pharm Biotechnol       Date:  2013       Impact factor: 2.837

7.  Mastomys natalensis Has a Cellular Immune Response Profile Distinct from Laboratory Mice.

Authors:  Tsing-Lee Tang-Huau; Kyle Rosenke; Kimberly Meade-White; Aaron Carmody; Brian J Smith; Catharine M Bosio; Michael A Jarvis; Heinz Feldmann
Journal:  Viruses       Date:  2021-04-22       Impact factor: 5.048

8.  Selective Protective Potency of Yersinia pestis ΔnlpD Mutants.

Authors:  S V Dentovskaya; S A Ivanov; P Kh Kopylov; R Z Shaikhutdinova; M E Platonov; T I Kombarova; T V Gapel'chenkova; S V Balakhonov; A P Anisimov
Journal:  Acta Naturae       Date:  2015 Jan-Mar       Impact factor: 1.845

9.  Induction of Protective Antiplague Immune Responses by Self-Adjuvanting Bionanoparticles Derived from Engineered Yersinia pestis.

Authors:  Xiuran Wang; Amit K Singh; Xiangmin Zhang; Wei Sun
Journal:  Infect Immun       Date:  2020-04-20       Impact factor: 3.441

Review 10.  Omics strategies for revealing Yersinia pestis virulence.

Authors:  Ruifu Yang; Zongmin Du; Yanping Han; Lei Zhou; Yajun Song; Dongsheng Zhou; Yujun Cui
Journal:  Front Cell Infect Microbiol       Date:  2012-12-13       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.